Cargando…

Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation

Rivaroxaban is an oral, direct Factor Xa inhibitor approved in the European Union and several other countries for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery and is in advanced clinical development for the treatment of thromboembolic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burghaus, Rolf, Coboeken, Katrin, Gaub, Thomas, Kuepfer, Lars, Sensse, Anke, Siegmund, Hans-Ulrich, Weiss, Wolfgang, Mueck, Wolfgang, Lippert, Joerg
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081290/ https://www.ncbi.nlm.nih.gov/pubmed/21526168 http://dx.doi.org/10.1371/journal.pone.0017626

Ejemplares similares

Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban—an oral, direct Factor Xa inhibitor
por: Burghaus, Rolf, et al.
Publicado: (2014)

Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban
por: Willmann, Stefan, et al.
Publicado: (2013)

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study
por: Willmann, Stefan, et al.
Publicado: (2018)

A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks
por: Eissing, Thomas, et al.
Publicado: (2011)

Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring
por: Mueck, Wolfgang, et al.
Publicado: (2013)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
por: Mueck, Wolfgang, et al.
Publicado: (2013)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
por: Willmann, Stefan, et al.
Publicado: (2021)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Development of a Physiologically Based Computational Kidney Model to Describe the Renal Excretion of Hydrophilic Agents in Rats
por: Niederalt, Christoph, et al.
Publicado: (2013)

Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification
por: Krauss, Markus, et al.
Publicado: (2013)

Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease
por: Willmann, Stefan, et al.
Publicado: (2022)

A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim
por: Niederalt, Christoph, et al.
Publicado: (2017)

Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
por: Willmann, Stefan, et al.
Publicado: (2018)

Predictive Performance of Physiology‐Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small‐Molecule Compounds in Children
por: Ince, Ibrahim, et al.
Publicado: (2021)

Baseline clusters and the response to positive airway pressure treatment in obstructive sleep apnoea patients: longitudinal data from the European Sleep Apnea Database cohort
por: Yassen, Ashraf, et al.
Publicado: (2022)

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism
por: Reinecke, Isabel, et al.
Publicado: (2020)

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism
por: Solms, Alexander, et al.
Publicado: (2020)

Comparative study of the effect of rivaroxaban and fondaparinux on monocyte’s coagulant activity and cytokine release
por: Laurent, Marc, et al.
Publicado: (2014)

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
por: Solms, Alexander, et al.
Publicado: (2019)

Data‐driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment
por: Fendt, Rebekka, et al.
Publicado: (2021)

Routine coagulation test abnormalities caused by rivaroxaban: A case report
por: Song, Zikai, et al.
Publicado: (2018)

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation
por: Kim, Paul Y., et al.
Publicado: (2018)

Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism
por: UCHIDA, Mona, et al.
Publicado: (2020)

Association between hypocalcemia and rivaroxaban in coagulation disorders: a case report
por: Pos, Alexandre Mio, et al.
Publicado: (2020)

Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the literature
por: Wu, Hai-Di, et al.
Publicado: (2019)

Effects of dabigatran and rivaroxaban on stroke severity according to the results of routine coagulation tests
por: Cho, Han-Jin, et al.
Publicado: (2020)

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
por: Yin, Lu, et al.
Publicado: (2022)

Integrating Cellular Metabolism into a Multiscale Whole-Body Model
por: Krauss, Markus, et al.
Publicado: (2012)

Effects of Rivaroxaban on Platelet Activation and Platelet–Coagulation Pathway Interaction: In Vitro and In Vivo Studies
por: Perzborn, Elisabeth, et al.
Publicado: (2015)

Standard coagulation assays alone are not sufficient to exclude surgically relevant rivaroxaban plasma concentrations
por: Kaserer, Alexander, et al.
Publicado: (2019)

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

A Mechanistic, Model-Based Approach to Safety Assessment in Clinical Development
por: Lippert, J, et al.
Publicado: (2012)

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
por: Willmann, Stefan, et al.
Publicado: (2019)

Aortic Aneurysm-associated Disseminated Intravascular Coagulation that Responded Well to a Switch from Warfarin to Rivaroxaban
por: Kadohira, Yasuko, et al.
Publicado: (2017)

Successful treatment of amniotic fluid embolism complicated by disseminated intravascular coagulation with rivaroxaban: A case report
por: Wu, Hai-Di, et al.
Publicado: (2020)

Rivaroxaban‐calibrated chromogenic anti‐Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation
por: Lucas, Fabienne, et al.
Publicado: (2021)

Unexpected Dynamic Binding May Rescue the Binding Affinity of Rivaroxaban in a Mutant of Coagulation Factor X
por: Zhang, Zhi-Li, et al.
Publicado: (2022)

Data-driven identification of heart failure disease states and progression pathways using electronic health records
por: Nagamine, Tasha, et al.
Publicado: (2022)

The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations
por: Ashton, Veronica, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9craoiqfdh7b90e22fja0mbi2a